Latest Content

A psychiatrist and psychiatric nurse practitioner discuss collaboration and patient support.

Check out the pipeline updates from April!

The FDA has approved Auvelity, an oral NMDA/sigma-1 therapy, offering a new option to curb Alzheimer disease agitation and ease caregiver burden.

Clinicians explore neuroscience-guided off-label prescribing.

DSM-6 forces psychiatry to choose: sharper science or softer labels. Explore why validity, biomarkers, and hierarchy matter for credibility.

The triple-blinded EPISODE trial with active placebo and 4 dosing regimens yielded mixed results, reflecting the challenge of discerning psilocybin effect and distinguishing between enlightenment and expectation.

New US patent backs Denovo’s ANK3 biomarker guiding DB104 for treatment‑resistant depression, highlighting promising efficacy in selected patients.

Lifestyle medicine pillars help reshape depression and anxiety treatment in psychiatry.

AI video screening spots early tardive dyskinesia signs, prompting clinical follow-up and treatment.

Spot ICU delirium early with MD‑MOSAIC—an exam for ventilated patients that sharpens diagnosis, prevents harm, and improves outcomes.

AI chatbots reshape therapy, pushing clinicians to unite around common change principles and connection.

Study links schizophrenia’s earlier onset to higher genomic deletion CNV burden, showing future potential for personalized care.

Round on the latest news in psychiatry from the last week.